ClinicalTrials.gg
RecruitingNCT06465550Updated Jun 24, 2024

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

A Phase 1 interventional study of BD211 in β-thalassemia, sponsored by Shanghai BDgene Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Shanghai BDgene Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2024, registered Jun 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
3 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.

Planned enrollment
23rd of 27
9 · median 30
Started
2024
with 7 others
Phase 1
10 of 32
6 open now
Primary completion
2026-12
later than 5 of 13 live
Registered
23rd of 32
by date
Lead sponsor
2 of 32
Shanghai BDgene Co., Ltd.

Among the 32 studies in Thalassemia with a site in China, this one is the 23rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2024, is one of 10 in phase 1, reaches primary completion later than 5 of the 13 other live ones, and was the 23rd registered.

Thalassemia

252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.

Browse Thalassemia studies →

Open to participants now

12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 3 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Thalassemia with a site in China, or all of them as a file.
02

Study summary

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Read the detailed description

This is an open-label, single-dose study of BD211 in patients with transfusion-dependent β-thalassemia aged 3 to 35 years. It is estimated that 9 subjects will be enrolled. BD211 is a gene modified gene therapy product designed to produce healthy β-globin in red blood cells in beta-thalassemia patients. The total follow-up duration was 18 months, the safe endpoints and effectiveness endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent β-thalassemia.

03

Conditions studied

  • β-thalassemia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 3 years (inclusive) to 18 years (exclusive), with no gender restrictions.
  2. Parents/legal guardians have fully understood and voluntarily signed a written form; and it is recommended that children aged 8 and above be involved in the decision to participate in this clinical trial and obtain a written consent form.
  3. Transfusion-dependent β-thalassemia patients. "Transfusion-dependent" is defined as: requiring at least 100 mL/kg of packed red blood cells annually; the genotype can be β0/β0, β0/β+, or β+/β+, diagnosed through studies.
  4. Eligible for hematopoietic stem cell transplantation, but without a donor or those refusing to undergo allogeneic hematopoietic stem cell transplantation.
  5. Have undergone symptomatic treatment for at least the past 2 years and have retained medical records including transfusion history.
  6. Stable condition and maintained an appropriate iron chelation regimen.
  7. Good status of organ function.
  8. Good compliance from the individual and parents/legal guardians, willing to adhere to visit schedules, trial plans, laboratory tests, and other trial procedures as stipulated in this protocol.
  9. Willing to participate in long-term follow-up research.

Exclusion criteria

Exclusion Criteria:

  1. Has a fully HLA-matched hematopoietic stem cell donor and is willing to receive a fully HLA-matched hematopoietic stem cell transplant. Enrollment is otherwise only advised after review by the safety review committee.
  2. Positive for antibodies against 1/2 (HIV-1/HIV-2), Treponema pallidum (TP) specific antibodies, Human T-lymphotropic Virus 1 or 2 (HTLV-1/HTLV-2) antibodies, and Vesicular Stomatitis Virus G (VSV-G).
  3. Positive for Virus (HBV) HbsAg or HBV-DNA; Virus (HCV) HCAb positive; positive nucleic acid test for Epstein-Barr Virus (EBV) or Cytomegalovirus (CMV).
  4. Severe active bacterial, viral, fungal, malarial, or parasitic infections.
  5. Has had, or currently has, a malignant, myeloproliferative, or immunodeficiency disorder.
  6. Direct relatives with known or suspected hereditary cancer syndromes (including but not limited to breast cancer, colorectal cancer, ovarian cancer, prostate cancer, and pancreatic cancer).
  7. diseases that could result in transfusion difficulties.
  8. Major organ diseases or abnormal lab tests, including:

    1. Liver cirrhosis, fibrosis, or active hepatitis, and/or abnormal liver function tests (Serum total (TBIL) ≥ 1.5x (ULN); (ALT) and Aspartate aminotransferase (AST) ≥ 2.5x ULN; Alkaline phosphatase ≥ 2.5x ULN).
    2. Heart disease, or (LVEF) \< 60%.
    3. Kidney diseases, or serum creatinine ≥ 1.5ULN, rate \< 30% of the normal level (measured or calculated by the Cockcroft-Gault equation).
    4. Endocrine disorders, such as insulin-dependent diabetes, hyperthyroidism, or hypothyroidism.
    5. Severe iron overload, serum ferritin ≥ 5000 ng/mL.
    6. Cardiac T2* \< 20 ms, and/or liver iron content (LIC) ≥ 15mg/g liver weight by MRI.
    7. Significant pulmonary hypertension diagnosed clinically according to guidelines, requiring clinical medical intervention.
  9. Uncorrected bleeding disorders.
  10. Severe psychiatric disorders.
  11. Peripheral blood white cell (WBC) count \< 3x10\^9/L or count \< 120x10\^9/L.
  12. Received hydroxyurea treatment within the last 3 months before stem cell collection.
  13. Used erythropoiesis-stimulating agents within the 3 months prior to HSC collection.
  14. History of transplantation.
  15. Previously received any type of gene and/or cell therapy.
  16. Participating in another clinical trial and is within a 30-day screening period.
  17. Has to anesthesia.
  18. Has contraindications to hematopoietic stem cell collection.
  19. Allergic to the drug or its .
  20. Any other conditions determined by the investigator as unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    BD211 Single-Dose group

    Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: ≥ 5×10\^6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211

    Genetic: BD211

Interventions

  • GeneticBD211

    Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

06

What researchers measure

Primary outcomes

  1. Mean time from BD211 treatment to successful neutrophil engraftment, as well as the number and percentage of participants with successful neutrophil engraftment.

    Definition of successful neutrophil engraftment: A consistent absolute neutrophil count (ANC) recovery of ≥0.5×10\^9/L over three consecutive days.

    Time frame: 18 months

  2. Mean time from BD211 treatment to successful platelet engraftment, as well as the number and percentage of participants with successful platelet engraftment.

    Definition of successful platelet engraftment: No platelet transfusion for 7 days with platelet counts of ≥20×10\^9/L in three consecutive measurements.

    Time frame: 18 months

  3. Proportion of participants achieving transfusion independence (TI)

    TI defined as "hemoglobin (Hb) ≥ 90g/L without any transfusion of packed red blood cells (pRBCs) for 12 months at any time during the study period after BD211 treatment"; proportion of participants with TI = number of participants with TI ÷ total number of BD211 treatment.

    Time frame: 18 months

Secondary outcomes

  1. BD211 transplant-related mortality (TRM) and overall survival (OS) after BD211 treatment.

    TRM = number of BD211 transplant-related deaths ÷ total number of BD211 treatment x 100% OS = number of all-cause deaths after BD211 treatment ÷ total number of BD211 treatment x 100%

    Time frame: 18 months

  2. Incidence of aberrant replication competent lentivirus (RCL) or malignant transformation induced by vector insertion after BD211 treatment.

    RCL positivity rate = number of RCL positive cases ÷ total number of BD211 treatment × 100%.

    Time frame: 18 months

  3. Total number of days hospitalized from the discharge day from LAFR to 18 months after BD211 administration

    The number of days of all-cause hospitalisation was calculated for each participant from the start of discharge from the transplantation unit after successful neutrophil and platelet engraftment to 18 months after BD211 treatment .

    Time frame: 18 months

  4. Types, numbers and incidence rate of adverse events (AEs) and serious adverse events (SAEs) that occurred within 18 months after BD211 adminstration.

    AEs and SAEs were evaluated per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.The frequency, severity, and correlation of AEs and SAEs with the investigational drug based on laboratory results and clinical manifestations were determined.

    Time frame: 18 months

  5. Mean duration (days) after participants reached TI

    Mean duration after reaching TI = sum of duration after reaching TI for all participants ÷ total number of participants.

    Time frame: 18 months

  6. Mean time required from BD211 treatment (D0) to achieve TI

    Mean time required from BD211 treatment (D0) to achieve TI = sum of time required from BD211 infusion (D0) to achieve TI ÷ total number of participants.

    Time frame: 18 months

  7. Mean Hb values after BD211 treatment

    Mean Hb of participants per month = sum of Hb (g/L) values of all participants per month ÷ total number of participants

    Time frame: 12 months~18months

  8. Proportion of participants with 60% and 80% reduction in blood transfusions from baseline

    The mean blood transfusion volume (mL/kg/year) in the 2 years prior to enrolment was used as the baseline, and compared with the mean blood transfusion volume (mL/kg/year) in the M12\~M18 period after receiving the BD211 infusion, and the proportion of participants whose blood transfusion volume was reduced by 60% and 80%, respectively, was calculated.

    Time frame: 12 months~18months

  9. Change in ferritin levels from baseline.

    Change in mean serum ferritin levels compared to baseline values at 6 months, 12 months and 18 months after BD211 treatment.

    Time frame: 18 months

  10. Expression of βA-T87Q globin protein in whole blood

    HPLC method was used to measure the expression of βA-T87Q globin protein in peripheral blood.

    Time frame: 18 months

  11. Mean VCN of the BD211 lentivirus vector in peripheral blood

    qPCR method were used to measure the VCN level of the BD211 lentivirus vector in peripheral blood.

    Time frame: 18 months

  12. Dose-response relationship

    The relationship between the BD211 dose and efficacy endpoints including TI outcome and expressed level of βA-T87Q globin protein (primarily PD biomarker) in blood were analyzed.

    Time frame: 18 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 20, 2024
StartActual
Jan 5, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06465550
Lead sponsor
Shanghai BDgene Co., Ltd.
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Jan 5, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 24, 2024

Study contacts

fujun Li
Contact
fujun.li@bdgene.cn
+86-19121311061
Sujiang Zhang, M.D.
principal investigator · Shanghai Ruijin Hospital, Shanghai Jiaotong University
Jianpei Fang, M.D.
principal investigator · Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion